高齢者の耐性トレーニングに対する反応の変動性に対する老化の生物学的メカニズムの影響 (BRIO)
高齢者(BRIO)における耐性トレーニングに対する反応の変動性に対する老化の生物学的メカニズムの影響:高齢者における進行性抵抗トレーニングの無作為化プラセボ対照試験。
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
調査の概要
詳細な説明
A 6-month, single blind, randomized, controlled multi-center clinical trial comparing a Health Education control intervention to a supervised Progressive Resistance Training intervention to test the central hypothesis that biological mechanisms of aging are mediators of exercise response heterogeneity in older adults.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Amanda Tweed
- 電話番号:507-255-6663
- メール:tweed.amanda@mayo.edu
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- 募集
- Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University
-
主任研究者:
- Roger Fielding, PhD
-
コンタクト:
- Arion Mete
- 電話番号:617-556-3237
- メール:arion.mete@tufts.edu
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
コンタクト:
- Amanda Tweed
- 電話番号:507-255-6663
- メール:tweed.amanda@mayo.edu
-
主任研究者:
- Nathan LeBrasseur, Ph.D, MS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- aged greater than or equal to 65 years
- sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity
- at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB
- willing to be randomized into HE or PRT
- willing to be transported or transport themselves to the clinical sites for the intervention and assessments
Exclusion Criteria:
- unwillingness to provide informed consent
- participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months
- an SPPB score of less than or equal to 3
- osteoarthritis or condition with joint pain limiting daily life activities
- significant weight loss or gain (7.5% of body weight) in past six months
- current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)
- clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the "normal limits', that are deemed to be of concern for participation in the study by the study physician
- acute or terminal illness
- Mini Mental State Exam (MMSE) <23
- myocardial infarction in the previous 6 months or other symptomatic coronary artery disease
- New York Heart Association Class III or IV congestive heart failure
- serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (>3 mm) on ECG
- chronic obstructive pulmonary disease requiring oxygen therapy
- upper or lower extremity fracture in the previous 6 months
- uncontrolled hypertension (150/90 mm Hg)
- neuromuscular diseases and/or drugs which affect neuromuscular function
- current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy
- allergy to lidocaine
- presence of significant liver or renal disease (eGFR < 45 mL/min)
- diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus
- HbA1c > 7%
- BMI <21 or >35 for men or >40 for women
- excessive alcohol intake (>14 alcoholic beverages per wk.)
- current tobacco use
- current participation in any interventional clinical trial
- current use of weight loss medications
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Progressive Resistance Training
participants will attend exercise session 3 times per week. |
3 times a week |
|
他の:Health Education
participants will attend health educations classed 1 time per week. |
once a week |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Precisely define the variability in changes in physical function
時間枠:baseline, 6 months
|
Measured by the Short Physical Performance Battery (SPPB), a 0-12 categorical scale of walking speed, standing balance, and repeated sit-to-stand time, with higher scores reflecting better physical function. |
baseline, 6 months
|
|
Precisely define the variability in changes in blood glucose concentrations in response to a meal tolerance test
時間枠:baseline, 6 months
|
Blood glucose concentrations (millimoles/liter) will be measured in response to a physiologically relevant meal challenge. Lower values are indicative of better metabolic health. |
baseline, 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Precisely define the variability in changes in skeletal muscle size.
時間枠:baseline, 6 months
|
Measured by computed tomography scans of the mid-thigh. Larger muscle cross-sectional area (cm^2) reflects a greater quantity of skeletal muscle. |
baseline, 6 months
|
|
Precisely define the variability in changes in skeletal muscle strength.
時間枠:baseline, 6 months
|
Measured by the one-repetition maximum, in newtons, on a leg press device, with higher scores reflecting greater skeletal muscle strength. |
baseline, 6 months
|
|
Precisely define the variability in changes in six-minute walk distance.
時間枠:baseline, 6 months
|
Measured by the distance (meters) walked in six minutes, with longer distances reflecting better physical function. |
baseline, 6 months
|
|
Precisely define the variability in insulin secretion in response to a mixed meal tolerance test.
時間枠:baseline, 6 months
|
Blood insulin concentrations (pmol/L) will be measured in response to a physiologically relevant meal challenge. Insulin concentrations in a physiological range reflect better metabolic health, while low insulin concentrations can reflect an impaired insulin response and high insulin concentrations can reflect peripheral insulin resistance. |
baseline, 6 months
|
|
Precisely define the variability in changes in the percentage of glycated hemoglobin in the blood.
時間枠:baseline, 6 months
|
Measured by the percentage of glycated hemoglobin in the blood (often referred to as HbA1c). A lower percentage of HbAlc reflects lower blood glucose concentrations over the past two to three months. |
baseline, 6 months
|
|
Precisely define the variability in changes in blood lipids.
時間枠:baseline, 6 months
|
Blood lipids, including total cholesterol, low density lipoproteins (LDLs), high density lipoproteins (HDLs), and triglycerides will be measured. Lower levels of total cholesterol (mg/dL), LDLs (mg/dL), and triglycerides (mg/dL), and higher levels of HDLs (mg/dL), are reflective of better metabolic health. |
baseline, 6 months
|
|
Precisely define the variability in changes in waist-to-hip ratio.
時間枠:baseline, 6 months
|
The circumference (cm) of the waist and hips will be measured and a ratio will be calculated. A lower waist-to-hip ratio is reflective of a better body composition (less central obesity or visceral fat). |
baseline, 6 months
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Nathan LeBrasseur, Ph.D, MS、Mayo Clinic
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。